Your browser doesn't support javascript.
loading
Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura.
Page, Evaren E; Kremer Hovinga, Johanna A; Terrell, Deirdra R; Vesely, Sara K; George, James N.
Afiliación
  • Page EE; Department of Biostatistics and Epidemiology, College of Public Health and Hematology-Oncology Section, Department of Medicine, College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK; and.
  • Kremer Hovinga JA; Department of Hematology and Central Hematology Laboratory, University Hospital of Bern, Department of Clinical Research, University of Bern, Bern, Switzerland.
  • Terrell DR; Department of Biostatistics and Epidemiology, College of Public Health and.
  • Vesely SK; Department of Biostatistics and Epidemiology, College of Public Health and.
  • George JN; Department of Biostatistics and Epidemiology, College of Public Health and Hematology-Oncology Section, Department of Medicine, College of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK; and.
Blood ; 127(24): 3092-4, 2016 06 16.
Article en En | MEDLINE | ID: mdl-27060171
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Púrpura Trombocitopénica Trombótica / Rituximab / Factores Inmunológicos Tipo de estudio: Diagnostic_studies / Etiology_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Púrpura Trombocitopénica Trombótica / Rituximab / Factores Inmunológicos Tipo de estudio: Diagnostic_studies / Etiology_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2016 Tipo del documento: Article